Oncotelic Therapeutics Engages IBN to Lead Corporate Communications Strategy
Oncotelic Therapeutics has selected IBN to manage its corporate communications as the company advances its RNA-based immunotherapy pipeline, including a Phase 3 pancreatic cancer treatment, highlighting strategic positioning for future clinical and regulatory milestones.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company, has announced its selection of IBN to lead corporate communications efforts. The company focuses on developing RNA-based immunotherapy and targeted treatments for cancer and underserved diseases, with particular emphasis on pediatric cancers and aggressive solid tumors.
The engagement with IBN, part of the Dynamic Brand Portfolio that includes specialized communications platform BioMedWire, represents a strategic move to enhance Oncotelic's market visibility. This partnership comes at a critical juncture as the company advances its lead candidate OT-101, currently in Phase 3 trials for pancreatic ductal adenocarcinoma, one of the most challenging oncology indications.
Under the leadership of Chairman and CEO Dr. Vuong Trieu, co-inventor of Abraxane, Oncotelic is building a multi-asset pipeline supported by its proprietary AI platform PDAOAI. The company's innovative approach extends beyond its directly owned programs, leveraging a 45% stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited capable of supporting regulatory filings for up to 20 drug candidates.
The corporate communications strategy through IBN will focus on highlighting Oncotelic's mission to address high-unmet-need cancers and rare pediatric indications. Dr. Trieu's extensive intellectual property portfolio, comprising over 150 patent applications and 39 issued U.S. patents, further strengthens the company's positioning in the competitive biopharmaceutical landscape.
This communications partnership signals Oncotelic's preparation for upcoming clinical milestones and potential regulatory interactions. The company's news and updates remain accessible through its dedicated newsroom at https://ibn.fm/OTLC, providing investors and stakeholders with ongoing transparency regarding development progress.
The selection of IBN, with its broad distribution network including article syndication to 5,000+ outlets and social media reach to millions of followers, demonstrates Oncotelic's commitment to effective stakeholder engagement as it progresses through late-stage clinical development and potential commercialization phases.